News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Teva to Acquire Allergan Generics, Withdraws from Mylan Deal

July 27, 2015

Article

July 27, 2015.

Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) has announced that it has signed a definitive agreement to acquire the generics business of Allergan (Dublin, Ireland) in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion. The Israeli firm simultaneously announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Amsterdam, The Netherlands). http://www.tevapharm.com/news_media/

Related Content

AI in Pharma: Where, When, and How Executives are Considering it

Gaugarin Oliver

November 19th 2024

Article

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problems

Mike Hollan

November 15th 2024

Article

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Leap Forward: Practical Gains for Pharma AI Use

Bianca Anghelina;Helen Merianos;Ruth Beadle

November 14th 2024

Article

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.